98%
921
2 minutes
20
Peritoneal dialysis (PD)-related peritonitis is a common complication of PD. Nonocclusive mesenteric ischemia (NOMI) is a rare complication of PD-related peritonitis, has a high mortality rate, and therefore should be detected early once it occurs. We describe a case of a 70-year-old woman on PD presented with moderate abdominal pain and low blood pressure, which contributed to the early diagnosis of PD-related peritonitis complicated with NOMI. Increased white cell count of 7150/μL (neutrophil, 84%) in dialysate effluent was diagnostic of PD-related peritonitis, which was later found to be caused by Pseudomonas putida. Computed tomography with contrast performed after administering crystalloids revealed hepatic portal venous gas, pneumatosis intestinalis in the ascending colon, and normal enhancement of the bowel wall and mesenteric arteries, which suggested a reperfusion of the previously ischemic ascending colon. Colonoscopy on hospital day seventeen revealed mucosal hemorrhage and ulcers in the entire right colon and the terminal ileum while the remaining colon was normal. These findings are compatible with the consequence of NOMI. Increased peak systolic velocity of the superior mesenteric artery (SMA) implied its stenosis. Past studies show that ischemia of the colon in patients with chronic kidney disease commonly occurs in the right colon. Arteriosclerosis of the SMA due to the long history of chronic kidney disease and diabetes might have caused its vulnerability to low blood pressure. Abdominal complications including NOMI should be screened for when a patient presents with low blood pressure and strong abdominal pain. This is the first case report that shows colonoscopy images of the colonic ulcers post-NOMI and PD-related peritonitis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829287 | PMC |
http://dx.doi.org/10.1007/s13730-020-00522-5 | DOI Listing |
Ren Fail
December 2025
Division of Nephrology, Department of Internal Medicine, Bursa Uludag University Faculty of Medicine, Bursa, Turkey.
Peritoneal dialysis (PD) and hemodialysis (HD) are the two primary renal replacement therapies for patients with end-stage renal disease (ESRD). While PD is an effective and convenient modality, long-term use can lead to ultrafiltration failure, recurrent peritonitis, and progressive structural alterations in the peritoneal membrane, necessitating a transition to HD. In recent years, rather than a complete transition, the combined use of PD and HD has emerged as a viable alternative, offering potential advantages for selected patient populations.
View Article and Find Full Text PDFIndian J Nephrol
September 2024
Department of Nephrology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), JIPMER Campus, Puducherry, India.
Background: Intraperitoneal vancomycin is commonly used to treat peritoneal dialysis (PD)-related peritonitis. Therapeutic drug level monitoring helps optimize the use of vancomycin in CKD patients. We studied whether sufficient serum levels were achieved in patients with PD-related peritonitis treated with the commonly used dose of vancomycin in patients with end stage renal disease.
View Article and Find Full Text PDFBMC Nephrol
September 2025
Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 11217, Taiwan.
Background: Encapsulating peritoneal sclerosis (EPS) can result in abdominal organ encasement, and bowel obstruction, and is associated with a high mortality rate. While various risk factors have been identified for the development of EPS, the factors influencing patient outcomes in EPS are less well-studied. This study aims to investigate the prognostic factors that affect the clinical course and survival of EPS patients.
View Article and Find Full Text PDFCureus
July 2025
Department of Nephrology, Nagasaki University Hospital, Nagasaki, JPN.
Herein, we report a case of peritoneal dialysis (PD)-related peritonitis caused by (). An 88-year-old man who had been receiving PD presented with cloudy effluent and an elevated dialysate white blood cell (WBC) count of 800/μL. He was diagnosed with PD-related peritonitis and treated with intraperitoneal cefazolin and ceftazidime, which promptly cleared the effluent by day 3 and reduced the WBC count in the dialysate to 0/μL by day 5.
View Article and Find Full Text PDFAm J Med Sci
August 2025
Nephrology and Hypertension Institute, Sheba Medical Center and Faculty of Medicine Tel Aviv University, Tel-Hashomer, Israel.
Background: C-reactive protein (CRP) is an acute inflammatory protein that increases in association with acute and chronic inflammation due to a range of causes, including infectious diseases and noninfectious inflammatory disorders and also in metabolic stresses. The purpose of this work was to determine whether acute CRP elevations above the baseline level in asymptomatic peritoneal dialysis (PD) patients could be associated with future short-term adverse events.
Methods: Medical records of chronic PD patients between the years 2012-2022 were reviewed retrospectively.